NPPA Approves Separate Price for GSK's New Paracetamol-Phenylephrine Sachet
New Delhi: The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has fixed the retail price of a new drug formulation, each sachet containing Paracetamol I.P. 500 mg and Phenylephrine HCl I.P. 10 mg, at Rs 6.96 for GlaxoSmithKline Asia Private Limited (GSK Asia).
The price notification was published in the Gazette of India on July 4, 2025.
As per the official order, the formulation qualifies as a new drug under Para 2(1)(u) of the Drugs (Prices Control) Order, 2013 (DPCO 2013).
The NPPA had received a price application from GSK Asia for the sachet-based fixed-dose combination formulation. The application was placed before the Multidisciplinary Committee of Experts during its 65th meeting (January 23, 2025), 66th meeting (March 3, 2025), and 68th meeting (June 3, 2025).
TABLE
S. No. | Medicines | Strength | Unit | Retail Price (in Rs.) |
(1) | (2) | (3) | (4) | (5) |
1 | Paracetamol and Phenylephrine Hydrochloride sachet | Each sachet containing Paracetamol I.P. 500 mg and Phenylephrine HCl I.P. 10 mg | 1 Sachet | 6.96 |
The official order further mandates that, “M/s GlaxoSmithKline Asia Private Limited shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.”
Retailers and dealers are required to display the price list prominently under Para 24(4) of the DPCO. Non-compliance with the price notification may attract penal provisions; “In case the price of the formulation... is not complied as per the instant price notification... M/s GlaxoSmithKline Asia Private Limited shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.”
The notified price is applicable exclusively to GSK Asia, subject to fulfillment of statutory requirements and valid manufacturing permissions from the Central or State Licensing Authority. Retailers must display the price list prominently in their premises. Non-compliance with the price notification may lead to recovery of the overcharged amount with interest under the DPCO 2013 read with the Essential Commodities Act, 1955.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.